Pacific Biosciences of California PACB Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 28.6%+4.4pp | 24.2%-2.1pp | 26.3%-18.1pp | 44.4%-6.0pp | |
| Operating margin | -346.2%-38.2pp | -308%-141pp | -166.8%+72.6pp | -239.4%-78.2pp | |
| Net margin | -341.5%-139pp | -202.7%-49.8pp | -153%+92.0pp | -244.9%-106pp | |
| Returns | |||||
| Return on equity | -213.5%-162pp | -51.7%-3.2pp | -48.5%-2.1pp | -46.4%-14.2pp | |
| Efficiency | |||||
| Asset turnover | 0.2×+0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Liquidity | |||||
| Current ratio | 5.1×-2.3× | 7.5×-0.3× | 7.8×+4.6× | 3.2×-12.1× | |
| Leverage | |||||
| Debt-to-equity | 10.7×+10.6× | 0×0.0× | 0.1×-1.6× | 1.7×+0.5× | |
| Per Share | |||||
| Book value per share | $0.02-99.0% | $1.76-36.5% | $2.77+10.3% | $2.51-35.3% | |
| Valuation | |||||
| Market capitalization | $496.96M+30.4% | $538.6M-79.4% | $2.62B+41.6% | $1.85B-58.9% | |
| Price / sales | 3.1×+0.6× | 3.5×-9.6× | 13.1×-1.4× | 14.4×-20.1× | |
| Price / book | 210×+206× | 1.1×-2.7× | 3.7×+0.4× | 3.3×-2.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Pacific Biosciences of California's profit margins?
- Pacific Biosciences of California (PACB) runs a 37.5% gross margin and a -83.3% operating margin, with a -80.3% net margin.
- Where do Pacific Biosciences of California's ratios come from?
- Every ratio is computed from Pacific Biosciences of California's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
